NCT00815932

Brief Summary

This is a controlled trial designed to determine short- and long-term effects of repeated tDCS on the P300 component of event-related evoked potentials in patients with chronic neuropathic pain due to Complex regional Pain Syndrome (CRPS) or diabetic neuropathy as compared with healthy subjects.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2016

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 30, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 31, 2008

Completed
7.7 years until next milestone

Study Start

First participant enrolled

September 1, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2017

Completed
Last Updated

October 5, 2017

Status Verified

October 1, 2017

Enrollment Period

1.1 years

First QC Date

December 30, 2008

Last Update Submit

October 3, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes in the amplitude of P300

    15 min after and 120 min after the 1st tDCS, 15 min after and 120 min after the 5st tDCS, and at the follow up 1 week after the 5th tDCS.

  • Changes in the Latency of P300

    15 min after and 120 min after the 1st tDCS, 15 min after and 120 min after the 5st tDCS, and at the follow up 1 week after the 5th tDCS.

Secondary Outcomes (2)

  • Changes in Pain Intensity-will be calculated as the difference in scores on the 11-point numerical pain rating scale (0-10)

    15 min after and 120 min after each tDCS stimulation

  • Changes in Pain Thresholds for Tactile and Thermal Stimuli will be calculated as the difference between ratings obtained form pain threshold measurements before- and after tDCS

    15 min after and 120 min after each tDCS stimulation

Study Arms (4)

1-CRPS

EXPERIMENTAL

10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb

Device: TDCS/sham procedure on five consecutive days

2-DN

EXPERIMENTAL

20 tDCS naïve patients with diabetic neuropathy

Device: TDCS/sham procedure on five consecutive days

3-RPNP

EXPERIMENTAL

20 tDCS naïve patients with resistant peripheral neuropathic pain

Device: TDCS/sham procedure on five consecutive days

4-CIPN

EXPERIMENTAL

10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients

Device: TDCS/sham procedure on five consecutive days

Interventions

The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.

1-CRPS2-DN3-RPNP4-CIPN

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • An affected upper limb or lower limb
  • Diagnosed as : Diabetic neuropathy, Complex Regional Pain Syndrome (CRPS), Chemotherapy Induced Pain Neuropathy (CIPN), Peripheral Neuropathy.
  • Have not responded to at least two medications of the following groups: Opioids. Tricyclics, SSRI, SNRI, Pregabalin, Gabapentin, Anticonvulsants.
  • Positive LANSS or CRPS criteria as follows:
  • Continuing pain which is disproportionate to any inciting event or for CRPS diagnosis.
  • Must report at least one symptom (symptoms here are reports by subject) in each of the four following categories: sensory, vasomotor, sudomotor/edema, motor/trophic.
  • Must display at least one sign (signs here refer to objective observation/testing) in in each of the four following categories: sensory, vasomotor, sudomotor/edema, motor/trophic;
  • Must meet resistant neuropathic pain criteria - pain that is neuropathic in characters that at least two neuropathic medications not from the same group have been tried for at least a month without improvement or severe side-effects were experienced. Resistant neuropathic pain with a score for "average pain in the last 24 hours" ≥4 on a numeric scale 0-10
  • tDCS naive

You may not qualify if:

  • Serious health problems other than CRPS or resistant neuropathic pain (e.g. uncontrolled hypertension, uncontrolled diabetes, heart failure)
  • Pain/painful conditions unrelated to CRPS or neuropathic pain
  • Pregnancy
  • History of seizures/epilepsy
  • Implanted device (e.g. pacemaker)
  • Active illicit drug/alcohol abuse
  • Unable to follow directions or complete tools in Hebrew
  • Previous exposure to tDCS stimulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pain and palliative care unit, Ben Gurion University of the Negev

Beersheba, 84105, Israel

Location

MeSH Terms

Conditions

Diabetic NeuropathiesCausalgia

Condition Hierarchy (Ancestors)

Peripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesComplex Regional Pain SyndromesAutonomic Nervous System DiseasesNeuralgia
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head Department of Family Medicine

Study Record Dates

First Submitted

December 30, 2008

First Posted

December 31, 2008

Study Start

September 1, 2016

Primary Completion

October 1, 2017

Study Completion

October 1, 2017

Last Updated

October 5, 2017

Record last verified: 2017-10

Locations